TY - JOUR T1 - 163 Lox-1-specific affimers block oxldl accumulation in vitro JF - Heart JO - Heart SP - A116 LP - A117 DO - 10.1136/heartjnl-2017-311726.162 VL - 103 IS - Suppl 5 AU - Jonathan De Siqueira AU - Izma Abdul Zani AU - David Russell AU - Stephen Wheatcroft AU - Darren Tomlinson AU - Shervanthi Homer-Vanniasinkam AU - Sreenivasan Ponnambalam Y1 - 2017/06/01 UR - http://heart.bmj.com/content/103/Suppl_5/A116.abstract N2 - Introduction Lectin-like oxidised low density lipoprotein receptor 1 (LOX-1, SREC-1, OLR1) is a class E scavenger which binds oxidised low density lipoproteins (oxLDL). It is expressed on endothelial cells, macrophages and smooth muscle cells, where it has a major role in sensing oxLDL, in the triggering of cellular dysfunction and in contribution to atherosclerosis. LOX-1 is thus an important target for the prevention and/or treatment of atherosclerosis. Affimers are synthetic protein scaffolds containing two hypervariable amino acid loops which enable recognition of a wide range of molecules. We aimed to investigate whether affimers specific for LOX-1 could be used to target oxLDL recognition and uptake using an in vitro cellular model.Methods Human embryonic kidney (HEK293T) and porcine aortic endothelial cells (PAEC) with tetracycline-inducible protein expression were engineered to expressed human LOX-1-FLAG construct. Isolated clonal lines for each cell type was checked using RT-PCR, immunoblotting and immunofluorescence microscopy. After overnight incubation with tetracycline (1 microgram/ml), cells were starved and incubated with=1,1‘-Dioctadecyl-3,3,3’,3’-Tetramethylindocarbocyanine Perchlorate (DiI)-labelled oxLDL (10 microgram/ml) for 30 min. Cells were fixed and imaged to characterise the uptake of OxLDL. Blocking experiments using 5 different affimers, was carried out by adding affimer prior to incubation with DiI-oxLDL. Effects on oxLDL binding and cellular accumulation was evaluated using fluorescence microscopy.Results The levels of LOX-1-FLAG mRNA were significantly raised (p<0.001) in both cell types in response to tetracycline. Porcine endothelial cells also had significant levels of endogenous native porcine LOX-1(Figure 1). The presence of human LOX-1-FLAG protein was confirmed by immunofluorescence microscopy (Figure 2a). Incubation with oxLDL demonstrated tetracycline-dependent labelled lipid particle uptake in HEK293T LOX-1-FLAG expressing cells. In contrast, oxLDL uptake was not significantly raised compared to uninduced baseline in PAEC LOX-1-FLAG expressing cells. Incubation with LOX-1 binding affimers led to a decrease in oxLDL uptake in both cell lines after induction of LOX-1-FLAG expression (Figure 2b).Conclusion We have successfully constructed two mammalian cell lines with a stable, inducible LOX-1 expression system. This has allowed us to demonstrate LOX-1-dependent oxLDL uptake. However, such expression is dependent on negligible expression of other scavenger receptors that mediate oxLDL binding and/or uptake. The use of LOX-1-specific affimers show that oxLDL binding and/or uptake is significantly decreased in both cell lines. Future experiments aim to determine the effects of such LOX-1-specific affimers in primary vascular cells and animal models in the context of atherosclerosis and vascular disease.Abstract 163 Figure 1 Relative mRNA levels of: A) Human LOX-1 in HEKs, B) Human LOX-1 in PAECs and C) Porcine LOX-1 in PAECsAbstract 163 Figure 2 Immunofluorescence Microscopy of HEK293T after induction with 1microgram/ml Tetracycline. A) Blue (DAPI) staining of nucleus and green (anti-FLAG) staining of FLAG-tagged LOX-1 B) Affimer effects on oxLDL (red) uptake. ER -